brukinsa aspen studi wm miss show superior imbruvica
achiev numer better vgpr os rate safeti profil data
surpris given lower expect vgpr rate better pfs/o overal wm small
indic import valuat standpoint expect formal approv
wm anticip off-label use given overal profil
make sever model tweak trim pt
trim wm sale global anticip approv base
aspen howev due attract profil would anticip off-label sale
pt employ price-to-earnings multipl discount rate ep
reflect year sustain profit
morn beigen announc phase aspen trial brukinsa vs imbruvica
waldenstrm macroglobulinemia wm meet primari endpoint show
statist signific improv cr/vgpr brukinsa show lower expect
vgpr rate overal wm popul vs imbruvica
vs r/r wm despit numer differ favor brukinsa
delta enough hit margin requir achiev superior
overal brukinsa vgpr rate lower anticip imbruvica slightli
better median follow-up month
note patient mutat lower expect
literatur report wm patient mutat prior studi
show imbruvica low vgpr rate mut patient pool
brukinsa encourag vgpr rate small sampl size
note studi power show statist signific improv
os unexpectedli brukinsa show numer statist signific benefit
os vs imbruvica consist brukinsa vgpr benefit
import os gold standard meaning clinician
rate r/r patient patient brukinsa vs
r/r patient patient imbruvica os rate
r/r patient patient brukinsa vs r/r patient
patient imbruvica
henc data show numer better rate vgpr os favor brukinsa
view pfs/o data somewhat compens lack superior orr
mean brukinsa may necessarili get formal approv believ
clinician abl interpret result show drug least
similar better imbruvica
pleas see page report import disclosur
zanubrutinib btk inhibitor tislelizumab antibodi approv china
respect fast follow offer high chanc approv
zanubrutinib may offer better profil imbruvica behind calquenc expect
phase result build confid zanu profil approv us
europ like pamiparib parp inhibitor promis gastric cancer
mainten sizabl overlook opportun phase gastric cancer import
driver stock data expect view stock offer de-risk
pipelin numer catalyst drive investor interest
zanu approv china mcl cll
top-line data zanu vs br
tisl approv china chl
tisl data
tisl data nscl china
zanubrutinib highli competit
market calquenc highli
pamiparib promis gastic cancer
peak sale po
tislelizumab modest seller
zanubrutinib found clinic
superior imbruvica sale
pamiparib work phase gastric
zanubrutinib found inferior
pamiparib fail gastric cancer
beigen unabl success
outsid china
beigen china-bas biotechnolog compani focus develop oncolog
drug serv global local market compani expertis cell biolog
chemistri gener pipelin four clinical-stag oncolog candid
candid direct valid oncolog target btk parp raf may
highli competit properti beigen use global reach in-licens
novel oncolog asset expand pipelin
recal kol note septemb therapeut confer
pay attent brukinsa differenti safeti toler aspen
confirm across check kol view drug overal safeti profil
key differenti could unseat imbruvica
aspen brukinsa vs imbruvica brukinsa four
patient discontinu treatment due fatal advers event vs imbruvica
nine patient discontinu due fatal advers event
importantli brukinsa lower rate atrial fibrillation/flutt minor
major bleed highli clinic meaning time brukinsa higher
rate diarrhea neutropenia manag
overal aspen posit studi brukinsa respect draw correl
potenti data cll especi physician inclin use safer btk inhibitor
view better efficaci plu
view aspen side show relev stock origin
anticip especi given deal remov financi overhang
provid beigen valid long-term pipelin focus oncolog china
step discuss fda/ema skeptic
approv anticip off-label usag given total data
beigen plan present detail data futur medic confer engag
regulatori author potenti file remain skeptic
drug approv given miss primari endpoint superior howev
would anticip obtain compendium list us would drive off-label
usag europ without formal approv could challeng
cut global sale project wm account lack formal
approv wm rare small market cut small revenu standpoint
recent data show brukinsa competit imbruvica
calquenc cll interim sequoia data expect alpin
interim data global sequoia studi test brukinsa vs br
cll expect expect top-line data includ analysi base prior
studi anticip brukinsa beat br less import
alpin head-to-head studi cll vs imbruvica
recal beigen show encourag safeti efficaci data brukinsa
arm sequoia cll complet studi cll arm
sequoia studi studi brukinsa mg bid high-risk cll patient
arm enrol patient origin target patient note
arm brukinsa venetoclax open accrual arm
addit beigen expect complet enrol global alpin phase
studi patient rel/ref cll/sll head-to-head imbruvica
earli alpin seek differenti brukinsa imbruvica orr cll
alpin brukinsa studi non-inferior imbruvica orr
endpoint met superior assess cr pr rate manag assum orr
cr pr imbruvica vs brukinsa ni ni met assum brukinsa
vs imbruvica superior
recal consult believ brukinsa need demonstr superior take share
imbruvica due physician familiar drug gener manag
toxic high respons imbruvica long-term follow-up studi set high
bar brukinsa beat studi base kol feedback
alpin also allow brukinsa differenti safeti better defin imbruvica
main achil heel toler safeti profil report
discontinu often occur treatment imbruvica due side effect lead
reduc toler toxic concern relat atrial fibril major
bleed risk hypertens diarrhea known off-target effect limit
pleas see note
updat zynteglo scd shines-brukinsa competitive-swtx/argx/rckt updat
cowen compani
beigen quarterli celgen product revlimid vidaza product xgeva kyproli blincyto novel drug sitravatinib lifirafenib grant royalti incom incom expens financi incom incom loss incom rate incom incom ep dilut compens net tax net ep share cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
beigen unprofit approv product like need rais addit
capit public market prior turn profit limit clinic trial
experi lead candid zanubrutinib moreov zanubrutinib face number
clinic regulatori commerci hurdl prior becom success project
futur sale zanubrutinib inher difficult
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success risk
outperform rate bgne share includ clinic setback on-going trial
zanubrutinib tislelizumab pamiparib failur obtain approv china
europ possibl addit financ chang appetit pre-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
